Skip to content
Daliresp, Daxas(roflumilast)
Daliresp, Daxas, Zoryve (roflumilast) is a small molecule pharmaceutical. Roflumilast was first approved as Daxas on 2010-07-05. It is used to treat chronic obstructive pulmonary disease in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against cAMP-specific 3',5'-cyclic phosphodiesterase 4B. In addition, it is known to target cAMP-specific 3',5'-cyclic phosphodiesterase 4D.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Daliresp, Zoryve (generic drugs available since 2018-07-13)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Roflumilast
Tradename
Company
Number
Date
Products
ZORYVEArcutis BiotherapeuticsN-215985 RX2022-07-29
1 products, RLD, RS
DALIRESPAstraZenecaN-022522 RX2011-02-28
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
dalirespNew Drug Application2020-03-12
roflumilastNew Drug Application2022-08-05
roflumilastANDA2023-05-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chronic obstructive pulmonary diseaseEFO_0000341D029424J44.9
Agency Specific
FDA
EMA
Expiration
Code
ROFLUMILAST, ZORYVE, ARCUTIS
2025-07-29NP
ROFLUMILAST, ROFLUMILAST, MSN
2023-04-18PC
ROFLUMILAST, ROFLUMILAST, HETERO LABS LTD III
2023-04-17PC
ROFLUMILAST, ROFLUMILAST, MYLAN
2023-04-17PC
ROFLUMILAST, ROFLUMILAST, STRIDES PHARMA
2023-04-17PC
Patent Expiration
Patent
Expires
Flag
FDA Information
Roflumilast, Zoryve, Arcutis
111298182037-08-25DPU-3408
98840502037-06-07DP
99077882037-06-07DPU-3408
109401422037-06-07DP
Roflumilast, Daliresp, Astrazeneca
85362062024-03-08U-1115
86040642024-03-08U-1115
86181422024-03-08DP
84311542023-02-19DP
94685982023-02-19DP
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03D: Other systemic drugs for obstructive airway diseases in atc
— R03DX: Other systemic drugs for obstructive airway diseases in atc
— R03DX07: Roflumilast
HCPCS
No data
Clinical
Clinical Trials
107 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.927189539
ObesityD009765EFO_0001073E66.91212—5
Chronic bronchitisD029481J42——11—2
EmphysemaD004646EFO_0000464J43———1—1
SarcoidosisD012507EFO_0000690D80-D89———1—1
Lung diseasesD008171EFO_0003818J98.4———1—1
Respiration disordersD012120J00-J99———1—1
Disease progressionD018450———1—1
Ulcerative colitisD003093EFO_0000729K51———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40294——13
AsthmaD001249EFO_0000270J45146——10
BronchiectasisD001987HP_0002110J47141——6
Type 2 diabetes mellitusD003924EFO_0001360E11111——3
Prediabetic stateD011236EFO_1001121R73.03——1——1
Diabetic nephropathiesD003928EFO_0000401——1——1
Diabetic neuropathiesD003929EFO_1000783——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L2012———3
DementiaD003704F03—2———2
Major depressive disorderD003865EFO_0003761F2211———1
Respiratory distress syndromeD012128EFO_1000637J80—1———1
AmnesiaD000647EFO_1001454F44.0—1———1
Cognitive dysfunctionD060825G31.84—1———1
Nervous system diseasesD009422G00-G9911———1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1———1
Metabolic syndromeD024821EFO_0000195E88.81—1———1
DermatitisD003872HP_0011123L30.9—1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Alzheimer diseaseD000544EFO_0000249F031———12
Neuronal plasticityD0094731————1
B-cell lymphomaD0163931————1
SchizophreniaD012559EFO_0000692F201————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameROFLUMILAST
INNroflumilast
Description
Roflumilast is a benzamide obtained by formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine. Used for treatment of bronchial asthma and chronic obstructive pulmonary disease. It has a role as a phosphodiesterase IV inhibitor and an anti-asthmatic drug. It is a member of benzamides, a chloropyridine, an aromatic ether, an organofluorine compound and a member of cyclopropanes.
Classification
Small molecule
Drug classantiasthmatics/antiallergics (not acting primarily as antihistamines): type IV phosphodiesterase
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
Identifiers
PDB1XOQ
CAS-ID162401-32-3
RxCUI1091836
ChEMBL IDCHEMBL193240
ChEBI ID47657
PubChem CID449193
DrugBankDB01656
UNII ID0P6C6ZOP5U (ChemIDplus, GSRS)
Target
Agency Approved
PDE4B
PDE4B
Organism
Homo sapiens
Gene name
PDE4B
Gene synonyms
DPDE4
NCBI Gene ID
Protein name
cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Protein synonyms
DPDE4, dunce-like phosphodiesterase E4, PDE32, phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)
Uniprot ID
Mouse ortholog
Pde4b (18578)
cAMP-specific 3',5'-cyclic phosphodiesterase 4B (Q8VBU5)
Alternate
PDE4D
PDE4D
Organism
Homo sapiens
Gene name
PDE4D
Gene synonyms
DPDE3
NCBI Gene ID
Protein name
cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Protein synonyms
cAMP-specific phosphodiesterase PDE4D6, DPDE3, PDE43, phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila), testicular tissue protein Li 136
Uniprot ID
Mouse ortholog
Pde4d (238871)
cAMP-specific 3',5'-cyclic phosphodiesterase 4D (Q8CG05)
Variants
Clinical Variant
No data
Financial
Daliresp - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,321 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,941 adverse events reported
View more details